Sandes et al. (2013) showed that the evaluation of blasts by MFC using the “CD34+ or CD117+ HLA-DR+” phenotypic profile cannot replace morphological blast count evaluation in MDS; instead, the combined use of both evaluation methods may provide complementary information, increasing the accuracy and reproducibility of bone marrow blast cell counts in these patients. The gene discussed is CD34; the disease is myelodysplastic syndrome.